A Prospective Research Investigation of Ischemia Using MCG

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
SB Technology, Inc.
Study ID
NCT06481943
Status
Recruiting
Apply to this trial

Conditions

  • Acute Coronary Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sponsor MCG device (CardiAQ) — DEVICE
    Unshielded magnetocardiography device for measuring cardiac magnetic fields

Study Details

PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.

Key Dates

Start date
Jul 11, 2024
Status verified
Oct 2025
Primary completion
Mar 31, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: ACS
    Adult patients who are undergoing a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute coronary syndrome (ACS). Patients are further classified as having low, medium, and high risk for ACS.

Primary Outcome Measure

Relationship between pre-procedural MCG and the peri-procedural angiography-based measures [ Time Frame: Data taken within 24 hours of each other ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Ghasaq Saleh, MD
[email protected]
5072552504
Mohamad A Alkhouli, MD, MBA (PRINCIPAL_INVESTIGATOR)
Mount Sinai HospitalNew YorkNew York10029
Sajiny John
[email protected]
631-750-6345

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MNMount Sinai Hospital· New York, NY

Related Studies